48.00 -0.28 (-0.58%)
Pre-market: 9:03AM EDT
|Bid||47.97 x 3200|
|Ask||48.02 x 1100|
|Day's range||0.00 - 0.00|
|Beta (3Y monthly)||0.78|
|PE ratio (TTM)||19.61|
|Forward dividend & yield||1.25 (2.59%)|
|1y target est||53.90|
Glaxo (GSK) provides updates on HIV regimens. FDA accepts Merck (MRK) & Sanofi's (SNY) regulatory applications for review.
Sunnova Energy International Inc. set terms for its planned initial public offering, saying in a regulatory filing it plans to offer 17.6 million shares priced at $16 to $18 each. The Houston-based solar energy company would raise $316.8 million at the top of that range. Seven banks are underwriting the deal, led by BofA Merrill Lynch, JPMorgan and Goldman Sachs. Proceeds will be used to pay down debt and for general corporate purposes.
European shares were little changed on Friday as drugmakers came under pressure on worries the U.S. government may intervene over high drug prices, while Federal Reserve chairman Jerome Powell's dovish comments helped limit losses. The pan-European STOXX 600 index ended flat but broke a five-week winning streak as regional equities failed to take advantage of the Fed's accommodative stance this week. Swiss stocks underperformed, sliding more than 1% as drugmakers including Roche Holdings, Novartis and Novo Nordisk fell more than 2%.
* European stocks fall after pharma stocks slide * STOXX 600 closes down 0.1%, healthcare stocks weigh: Siemens Healthineers -6% * Autos drag Germany's DAX 0.3% lower * UK housebuilders rise on upbeat survey * Indivior soars after lifting profit guidance, Reckitt rises after U.S. settlement Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Thyagaraju Adinarayan. Reach him on Messenger to share your thoughts on market moves: firstname.lastname@example.org CLOSING SNAPSHOT: EUROPE CLOSES AT 2-WEEK LOW (1601 GMT) Profit taking in pharma stocks has derailed the Powell-induced gains, pushing the STOXX 600 into the red in late afternoon trade and to its lowest close since June 28.
* European stocks fall after pharma stocks slide * STOXX 600 down 0.2%, healthcare stocks weigh: Siemens Healthineers -7% * Autos drag Germany's DAX 0.3% lower * UK housebuilders rise on upbeat survey * Indivior soars after lifting profit guidance, Reckitt rises after U.S. settlement Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Thyagaraju Adinarayan. Reach him on Messenger to share your thoughts on market moves: email@example.com HEALTH CHECK FOR PHARMA AS U.S. SHIFTS FOCUS TO HIGH DRUG PRICES (1527 GMT) European pharma stocks are taking a hit this afternoon on worries that U.S. Congress will now look at doing something about high drug prices.
European shares closed at a two-week low on Thursday weighed down by pharma stocks on worries that U.S. government may intervene on high drug prices, while optimism from the Federal Reserve's dovish stance faded away. The pan-European stocks benchmark rallied earlier in the day on remarks from Fed Chair Jerome Powell but reversed course in late afternoon trading to close 0.1% lower. The White House announced that it was ditching its push for changes to the pharma rebate structure, providing some relief to health insurance companies but hurting drugmakers, including those in Europe.
The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.
Dividend paying stocks like Novo Nordisk A/S (CPH:NOVO B) tend to be popular with investors, and for good reason...
In the first-quarter earnings investor presentation, Novo Nordisk (NVO) guided for YoY operating profit growth of 2% to 5%.
Novo Nordisk's (NVO) Esperoct gets EU approval for the treatment of adolescents (less-than or equal-to 12 years of age) and adults with haemophilia A.
Pfizer (PFE) announces definitive deal buy Array BioPharma. Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) win approvals for new drugs/line extensions.
Gilead (GILD) collaborates with Nurix Therapeutics to leverage the proprietary drug discovery platform of the latter to identify novel agents that induce degradation of specified drug targets.
Novo Nordisk's (NVO) Victoza gets FDA approval for the treatment of pediatric patients aged 10 years or older with type II diabetes.
Shares of gene-therapy companies shot up on Monday after Pfizer Inc. announced it would acquire cancer drug maker Array BioPharma Inc. in a deal worth up to $11.4 billion.
The U.S. Food and Drug Administration on Monday approved Novo Nordisk's Victoza, a liraglutide injection, for the treatment of young patients 10 years or older with Type 2 diabetes. Although Victoza has been FDA-approved to treat adults with Type 2 diabetes since 2010, it is the only non-insulin drug approved for children other than metformin, which was approved for pediatric use in 2000. "Victoza has now been shown to improve blood sugar control in pediatric patients with Type 2 diabetes. The expanded indication provides an additional treatment option at a time when an increasing number of children are being diagnosed with this disease," said Lisa Yanoff, acting director of the Division of Metabolism and Endocrinology Products in the FDA's Center for Drug Evaluation and Research. Type 2 diabetes occurs when the pancreas is unable to make enough insulin to keep blood sugar at normal levels. It's the most common form of diabetes, normally occurring in patients 45 years or older. However, in the past two decades, its prevalence among younger patients has dramatically risen. More than 5,000 new cases of Type 2 diabetes are now diagnosed each year in the U.S. among people younger than age 20, according to the Centers for Disease and Control and Prevention. Shares of Novo Nordisk have gained 10.8% so far this year, while the SPDR S&P Pharmaceuticals ETF has gained 3%. The Dow Jones Industrial Average has gained 11.8% and the S&P 500 has gained 15.3%.
Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.